When last I left Bicycle Therapeutics (NASDAQ: BCYC ), I was optimistic about the potential for the investment thesis, given their strong cash position and some encouraging early-stage data in theirI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in th ...